These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29176511)

  • 1. Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio.
    Molfenter T; Sherbeck C; Starr S; Kim JS; Zehner M; Quanbeck A; Jacobson N; McCarty D
    J Addict Med; 2018; 12(2):85-91. PubMed ID: 29176511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
    Molfenter T; Sherbeck C; Zehner M; Quanbeck A; McCarty D; Kim JS; Starr S
    Subst Abuse Treat Prev Policy; 2015 Mar; 10():13. PubMed ID: 25884206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial.
    Molfenter T; Kim JS; Quanbeck A; Patel-Porter T; Starr S; McCarty D
    Implement Sci; 2013 May; 8():50. PubMed ID: 23663749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The payer's role in addressing the opioid epidemic: It's more than money.
    Molfenter T; McCarty D; Jacobson N; Kim JS; Starr S; Zehner M
    J Subst Abuse Treat; 2019 Jun; 101():72-78. PubMed ID: 31174716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.
    Knudsen HK; Studts JL
    J Behav Health Serv Res; 2019 Jan; 46(1):151-163. PubMed ID: 30069622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.
    Abraham AJ; Andrews CM; Grogan CM; Pollack HA; D'Aunno T; Humphreys K; Friedmann PD
    Psychiatr Serv; 2018 Apr; 69(4):448-455. PubMed ID: 29241428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.
    Molfenter T; Fitzgerald M; Jacobson N; McCarty D; Quanbeck A; Zehner M
    J Psychoactive Drugs; 2019; 51(3):272-279. PubMed ID: 30732542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
    Gastfriend DR
    Ann N Y Acad Sci; 2014 Oct; 1327(1):112-30. PubMed ID: 25236185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16.
    Yang JC; Roman-Urrestarazu A; Brayne C
    PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using behavioral economics to predict opioid use during prescription opioid dependence treatment.
    Worley MJ; Shoptaw SJ; Bickel WK; Ling W
    Drug Alcohol Depend; 2015 Mar; 148():62-8. PubMed ID: 25622776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
    Kenworthy J; Yi Y; Wright A; Brown J; Maria Madrigal A; Dunlop WCN
    J Med Econ; 2017 Jul; 20(7):740-748. PubMed ID: 28489467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policies related to opioid agonist therapy for opioid use disorders: The evolution of state policies from 2004 to 2013.
    Burns RM; Pacula RL; Bauhoff S; Gordon AJ; Hendrikson H; Leslie DL; Stein BD
    Subst Abus; 2016; 37(1):63-9. PubMed ID: 26566761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
    Bachireddy C; Terplan M
    Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
    Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public policy statement on buprenorphine for opiate dependence and withdrawal.
    J Addict Dis; 2004; 23(4):116-7. PubMed ID: 15534969
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on pharmacotherapy for treatment of opioid use disorder.
    Ayanga D; Shorter D; Kosten TR
    Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare utilization and costs associated with treatment for opioid dependence.
    Shah A; Duncan M; Atreja N; Tai KS; Gore M
    J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.